RE:The SMOKING Gun!!! A little further down, they state.....
"By combining the two groups to create Biodexa Pharmaceuticals, we have the opportunity to reposition the enlarged group as an emerging biotech company focused on the development of therapeutics for rare diseases, supported by Midatech and Bioasis' enabling drug delivery platforms....In combination with Bioasis' promising development pipeline we have the opportunity to create a much stronger group and transition from a drug delivery platform-based company to a therapeutics company."
So I read it a bit differently. So I think they are saying they are transitioning away from THEIR drug delivery strategy (Q-Sphera) to "development of therapeutics for rare diseases" which includes "Bioasis' enabling drug delivery platforms".